153 related articles for article (PubMed ID: 30549356)
21. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
Lempinen M; Lyytinen I; Nordin A; Tervahartiala T; Mäkisalo H; Sorsa T; Isoniemi H
Ann Med; 2013 Nov; 45(7):482-7. PubMed ID: 23962148
[TBL] [Abstract][Full Text] [Related]
22. Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality.
Hästbacka J; Linko R; Tervahartiala T; Varpula T; Hovilehto S; Parviainen I; Vaara ST; Sorsa T; Pettilä V
Anesth Analg; 2014 Apr; 118(4):790-8. PubMed ID: 24651234
[TBL] [Abstract][Full Text] [Related]
23. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
24. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression.
Go C; Schwartz MR; Donovan DT
Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):298-302. PubMed ID: 12731623
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
26. Serum matrix metalloproteinase-8, tissue inhibitor of metalloproteinase and myeloperoxidase in ischemic stroke.
Palm F; Pussinen PJ; Safer A; Tervahartiala T; Sorsa T; Urbanek C; Becher H; Grau AJ
Atherosclerosis; 2018 Apr; 271():9-14. PubMed ID: 29453088
[TBL] [Abstract][Full Text] [Related]
27. Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma.
Nurmenniemi S; Koivula MK; Nyberg P; Tervahartiala T; Sorsa T; Mattila PS; Salo T; Risteli J
Oral Oncol; 2012 Feb; 48(2):136-40. PubMed ID: 21945070
[TBL] [Abstract][Full Text] [Related]
28. Association of Matrix Metalloproteinases -7, -8 and -9 and TIMP -1 with Disease Severity in Acute Pancreatitis. A Cohort Study.
Nukarinen E; Lindström O; Kuuliala K; Kylänpää L; Pettilä V; Puolakkainen P; Kuuliala A; Hämäläinen M; Moilanen E; Repo H; Hästbacka J
PLoS One; 2016; 11(8):e0161480. PubMed ID: 27561093
[TBL] [Abstract][Full Text] [Related]
29. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
30. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence.
Pussinen PJ; Sarna S; Puolakkainen M; Öhlin H; Sorsa T; Pesonen E
Int J Cardiol; 2013 Jul; 167(2):362-8. PubMed ID: 22257687
[TBL] [Abstract][Full Text] [Related]
31. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53.
Rady PL; Schnadig VJ; Weiss RL; Hughes TK; Tyring SK
Laryngoscope; 1998 May; 108(5):735-40. PubMed ID: 9591556
[TBL] [Abstract][Full Text] [Related]
32. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma.
Yoshizaki T; Maruyama Y; Sato H; Furukawa M
Int J Cancer; 2001 Jan; 95(1):44-50. PubMed ID: 11241310
[TBL] [Abstract][Full Text] [Related]
33. Serum tissue-degrading proteinases and incident cardiovascular disease events.
Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
[TBL] [Abstract][Full Text] [Related]
34. Laryngeal distribution of recurrent respiratory papillomatosis in a previously untreated cohort.
Benedict PA; Ruiz R; Yoo M; Verma A; Ahmed OH; Wang B; Dion GR; Voigt A; Merati A; Rosen CA; Amin MR; Branski RC
Laryngoscope; 2018 Jan; 128(1):138-143. PubMed ID: 28714564
[TBL] [Abstract][Full Text] [Related]
35. p16 Influence on Laryngeal Squamous Cell Carcinoma Relapse and Survival.
Sánchez Barrueco A; González Galán F; Villacampa Aubá JM; Díaz Tapia G; Fernández Hernández S; Martín-Arriscado Arroba C; Cenjor Español C; Almodóvar Álvarez C
Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1042-1047. PubMed ID: 30642220
[TBL] [Abstract][Full Text] [Related]
36. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Allen CT; Lee S; Norberg SM; Kovalovsky D; Ye H; Clavijo PE; Hu-Lieskovan S; Schlegel R; Schlom J; Strauss J; Gulley JL; Trepel J; Hinrichs CS
J Immunother Cancer; 2019 May; 7(1):119. PubMed ID: 31053174
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases -8 and -9 and tissue inhibitor of metalloproteinase-1 in burn patients. A prospective observational study.
Hästbacka J; Fredén F; Hult M; Bergquist M; Wilkman E; Vuola J; Sorsa T; Tervahartiala T; Huss F
PLoS One; 2015; 10(5):e0125918. PubMed ID: 25945788
[TBL] [Abstract][Full Text] [Related]
39. Natural History and Malignant Transformation in Recurrent Respiratory Papillomatosis: Human Papillomavirus (HPV), Dysplasia and an Autopsy Review.
Can NT; Tretiakova MS; Taxy JB
Fetal Pediatr Pathol; 2015 Apr; 34(2):80-90. PubMed ID: 25353697
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
